ClinicalTrials.gg
Not yet recruitingNCT07352566Updated Jun 3, 2026

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

A Phase 4 interventional study of In situ cutaneous microdevice and Triamcinolone in Psoriasis and Atopic Dermatitis, sponsored by University of California, San Francisco. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by University of California, San Francisco · Phase 4, Interventional, and Device feasibility

How we know · 36 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Psoriasis by University of California, San Francisco — 6 open to participants now, 6 under way, none of them phase 3. Psoriasis · University of California, San Francisco.

Planned enrollment
12th of 17
10 · median 18
Started
2026
with 2 others
Phase 4
11 of 18
5 open now
Registered
16th of 18
by date

Among the 18 studies in Psoriasis by University of California, San Francisco, this one is the 12th largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 in phase 4, and was the 16th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 18 studies in Psoriasis by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Psoriasis by University of California, San Francisco, or all of them as a file.
02

Study summary

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.

The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

03

Conditions studied

  • Psoriasis
  • Atopic Dermatitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

> 18 years of age patients with atopic dermatitis or psoriasis if female patient with child bearing potential (on oral pills or intrauterine device for at least 30 days)

Exclusion Criteria: None

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    In situ cutaneous microdevice

    The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

    Device: In situ cutaneous microdevice · Drug: Triamcinolone · Drug: 5-Fluorouracil · Drug: Calcipotriene · Drug: Tapinarof · Drug: Crisaborole · Drug: Tacrolimus · Drug: Adalimumab · Drug: Etanercept · Drug: Certolizumab · Drug: Infliximab · Drug: Secukinumab · Drug: Ixekizumab · Drug: Apremilast · Drug: Risankizumab · Drug: Ustekinumab · Drug: Hydroxychloroquine · Drug: Methotrexate · Drug: Mycophenolate · Drug: Azathioprine · Drug: Chloroquine · Drug: Cyclosporine · Drug: Tofacitinib · Drug: Deucravacitinib · Drug: Dupilumab · Drug: Tralokinumab · Drug: Guselkumab · Drug: Tildrakizumab · Drug: Baractinib · Drug: Abrocitinib · Drug: Upadacitinib · Drug: Lebrikizumab · Drug: Nemolizumab · Drug: Ruxolitinib · Drug: Bimekizumab · Drug: Roflumilast

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    The safety of microdevice placement and removal will be based on assessment of adverse events.

    Time frame: 1 year

  2. Proportion of retrieved devices with assessable tissue

    The feasibility of microdevice analysis based on the ability to place and retrieve the device with sufficient tissue, of sufficient quality, for downstream histopathology/molecular analysis and interpretation of at least 80% of the device reservoirs.

    Time frame: 1 year

Secondary outcomes

  1. Change in local skin inflammation (molecular assays)

    Feasibility of utilizing quantitative histopathologic assessment and/or transcriptional profiling to determine whether there is local change in lesional rash-affected skin with clinically relevant skin inflammation treating agents.

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Publications

  • Tsai LL, Phillips WW, Hung YP, Dominas C, Deans K, Ahn S, Ferland B, Weiss K, Lanuti M, Auchincloss H, Schumacher L, Jonas O, Colson YL. First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer. Ann Surg. 2023 May 1;277(5):e1143-e1149. doi: 10.1097/SLA.0000000000005385. Epub 2023 Apr 6. PubMed 35129472 ↗
  • Tatarova Z, Blumberg DC, Korkola JE, Heiser LM, Muschler JL, Schedin PJ, Ahn SW, Mills GB, Coussens LM, Jonas O, Gray JW. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs. Nat Biotechnol. 2022 Dec;40(12):1823-1833. doi: 10.1038/s41587-022-01379-y. Epub 2022 Jul 4. PubMed 35788566 ↗
  • Peruzzi P, Dominas C, Fell G, Bernstock JD, Blitz S, Mazzetti D, Zdioruk M, Dawood HY, Triggs DV, Ahn SW, Bhagavatula SK, Davidson SM, Tatarova Z, Pannell M, Truman K, Ball A, Gold MP, Pister V, Fraenkel E, Chiocca EA, Ligon KL, Wen PY, Jonas O. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas. Sci Transl Med. 2023 Sep 6;15(712):eadi0069. doi: 10.1126/scitranslmed.adi0069. Epub 2023 Sep 6. PubMed 37672566 ↗
  • Jonas O, Landry HM, Fuller JE, Santini JT Jr, Baselga J, Tepper RI, Cima MJ, Langer R. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci Transl Med. 2015 Apr 22;7(284):284ra57. doi: 10.1126/scitranslmed.3010564. PubMed 25904741 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jun 2030, 46 months later.

Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 46 months is above that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Jan 20, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Jun 1, 2030
CompletionEst.
Jun 1, 2030
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07352566
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Jun 1, 2030 (estimated)
Completion
Jun 1, 2030 (estimated)
Last update
Jun 3, 2026

Study contacts

Raymond Cho, MD, PhD
Contact
raymond.cho@ucsf.edu
415-353-7800
Jeffrey Cheng, MD, PhD
Contact
jeffrey.cheng@ucsf.edu
415-575-0524
Raymond Cho, MD, PhD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Triamcinolone · Fluorouracil · Calcipotriene · Tapinarof · Crisaborole · Tacrolimus · Adalimumab · Etanercept · Certolizumab Pegol · Infliximab · Secukinumab · Ixekizumab · Apremilast · Risankizumab · Ustekinumab · Hydroxychloroquine · Methotrexate · Mycophenolic Acid · Azathioprine · Chloroquine · Cyclosporine · Tofacitinib · Deucravacitinib · Dupilumab · Tralokinumab · Guselkumab · Tildrakizumab · Abrocitinib · Upadacitinib · Lebrikizumab · Nemolizumab · Ruxolitinib · Bimekizumab · Roflumilast

Start the discussion